|
Curbing The Cardiovascular Disease Epidemic: Aligning Industry, Government, Payers, And Academics
Robert M. Califf,
Robert A. Harrington,
Leanne K. Madre,
Eric D. Peterson,
Deborah Roth and
Kevin A. Schulman
Despite decades of progress in the diagnosis, treatment, and prevention of cardiovascular disease, its prevalence continues to grow in both developed and developing countries. We have constructed a model, the "cycle of quality," which connects the innovation of initial scientific discovery with validated methods of translating research into effective delivery. This model can serve as a basis for evaluating proposed efforts to improve interactions among private and public aspects of health care to accelerate development and appropriate adoption of new treatments, and to achieve greater penetration of effective behavioral therapies and established technologies, resulting in major improvements in cardiovascular health.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
R. M. Califf and G. S. Ginsburg
Organizational Improvements to Enhance Modern Clinical Epidemiology
JAMA,
November 19, 2008;
300(19):
2300 - 2302.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Peto, J. Emberson, M. Landray, C. Baigent, R. Collins, R. Clare, and R. Califf
Analyses of Cancer Data from Three Ezetimibe Trials
N. Engl. J. Med.,
September 25, 2008;
359(13):
1357 - 1366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. K. Nallamothu, R. A. Hayward, and E. R. Bates
Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies
Circulation,
September 16, 2008;
118(12):
1294 - 1303.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Himmelfarb
Chronic Kidney Disease and the Public Health: Gaps in Evidence From Interventional Trials
JAMA,
June 20, 2007;
297(23):
2630 - 2633.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Califf
The cycle of quality as a model for improving health outcomes in the treatment of hypertension
Eur. Heart J. Suppl.,
May 1, 2007;
9(suppl_B):
B8 - B12.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Eisenstein, D. F. Kong, K. J. Anstrom, and R. M. Califf
Clopidogrel and Long-term Outcomes After Drug-Eluting Stent Implantation--Reply
JAMA,
April 25, 2007;
297(16):
1770 - 1771.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. Mahaffey and R. A. Harrington
Optimal Timing for Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: Questions, Answers, and More Questions
JAMA,
February 14, 2007;
297(6):
636 - 639.
[Full Text]
[PDF]
|
|
|
|
